deltatrials
Completed PHASE2 NCT00263263

RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.

Phase 2 Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Degenerated Saphenous Vein Grafts

Sponsor: Antwerp Cardiovascular Institute Middelheim

Conditions Coronary Artery Disease Saphenous Vein Graft Disease Stable Angina Unstable Angina
Interventions bare metal stent sirolimus-eluting stent
Updated 5 times since 2017 Last updated: Mar 12, 2007 Started: Sep 30, 2003 Completion: Dec 31, 2005

A PHASE2 clinical study on Coronary Artery Disease and Saphenous Vein Graft Disease, this trial is completed. The trial is conducted by Antwerp Cardiovascular Institute Middelheim and has accumulated 5 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Antwerp Cardiovascular Institute Middelheim
Data source: Antwerp Cardiovascular Institute Middelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Antwerp, Belgium